Related Experiment Video
Updated: Mar 24, 2026
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Long non-coding RNA-MIR3142HG as a novel biomarker for assessing disease activity in children with Crohn's disease
Xue Qiao1, Weiying Zhang2, Wenxin Chen1
1Department of Gastroenterology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Insights
Long non-coding RNA MIR3142HG shows promise as a biomarker for pediatric Crohn's disease activity. Elevated levels in serum and intestinal tissue correlate with disease severity, aiding in patient assessment.
Area of Science:
- Gastroenterology and Hepatology
- Molecular Biology
- Biomarker Discovery
Background:
- Pediatric Crohn's disease (CD) requires reliable biomarkers for assessing disease activity.
- Current assessment methods can be invasive or lack sensitivity.
- Long non-coding RNAs (lncRNAs) are emerging as potential diagnostic and prognostic tools in various diseases.
Purpose of the Study:
- To investigate the potential of lncRNA-MIR3142HG as a novel biomarker for disease activity in pediatric CD.
- To evaluate the correlation between lncRNA-MIR3142HG expression and clinical/endoscopic indices of disease severity.
- To assess the diagnostic efficacy of lncRNA-MIR3142HG in pediatric CD patients.
Main Methods:
- Serum and intestinal mucosal samples were collected from 119 children (CD and non-CD groups).
- lncRNA-MIR3142HG expression was quantified using RT-qPCR.
- Clinical (PCDAI) and endoscopic (SES-CD) activity, histopathology (Chiu's score), and Occludin expression were assessed.
Main Results:
- lncRNA-MIR3142HG expression was significantly higher in pediatric CD patients compared to controls (p < 0.05).
- Intestinal and serum lncRNA-MIR3142HG levels positively correlated with PCDAI, SES-CD, and Chiu's scores, and negatively with Occludin expression (p < 0.05).
- Receiver operating characteristic (ROC) curve analysis demonstrated the efficacy of lncRNA-MIR3142HG in evaluating disease activity.
Conclusions:
- Both serum and intestinal mucosal lncRNA-MIR3142HG are potential biomarkers for assessing clinical and endoscopic activity in pediatric CD.
- Combined assessment of lncRNA-MIR3142HG with fecal calprotectin may offer superior efficacy.
- lncRNA-MIR3142HG holds promise for non-invasive monitoring of pediatric Crohn's disease activity.
Objectives:
This study aimed to investigate the potential of long non-coding RNAs (lncRNA)-MIR3142HG as a novel biomarker for assessing disease activity in pediatric Crohn's disease (CD).
Methods:
A total of 119 children suspected of having CD who visited the outpatient department of the affiliated Children's Hospital of Nanjing Medical University from September 2022 to March 2025 and were classified into CD and non-CD groups based on clinical diagnosis. Serum and intestinal mucosal samples were collected, and lncRNA-MIR3142HG expression was quantified using real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR). Clinical activity and endoscopic activity were similarly assessed using the pediatric Crohn's disease activity index (PCDAI) and simplified endoscopic score for CD (SES-CD). Correlations between lncRNA-MIR3142HG levels and clinical indices, including Chiu's histopathological score and Occludin protein expression, were analyzed, with receiver operating characteristic curve area under the curve values calculated for evaluation efficacy.
Results:
LncRNA-MIR3142HG expression was significantly elevated in the CD group compared to non-CD and control groups (p < 0.05). Intestinal mucosal lncRNA-MIR3142HG was positively correlated with PCDAI, SES-CD, and Chiu's scores (p < 0.05) and negatively with Occludin expression (p < 0.05). Serum lncRNA-MIR3142HG also showed positive correlations with PCDAI and Chiu's scores (p < 0.05) and a negative correlation with Occludin (p < 0.05).
Conclusions:
This study indicated that both serum and intestinal mucosal lncRNA-MIR3142HG, alone or combined with fecal calprotectin, may be useful for evaluating clinical and endoscopic activity in pediatric CD, with combined assessments yielding superior efficacy.
